Celgene (CELG) Closes Up 8.4%
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Join SI Premium – FREE
Celgene (Nasdaq: CELG) closes up 8.4% today on volume that was over four times as strong as Celgene's average daily volume. Celgene is trading at its highest level since October 2007.
Celgene's shares rose as potential competitor to CELG's bone-marrow cancer treatment in Europe failed a late-stage clinical trial. Its rival SuperGen (Nasdaq: SUPG) said Dacogen didn't improve the survival rate of patients. SuperGen's stock closed down 14.63% to a low of $1.75.
Celgene Corporation is an integrated biopharmaceutical company.
SuperGen is a pharmaceutical company dedicated primarily to the discovery, development and commercialization of therapies to treat patients with cancer.
Sign up at EasyStockAlerts.com To Be Alerted To Your Breaking Stock News!
Celgene's shares rose as potential competitor to CELG's bone-marrow cancer treatment in Europe failed a late-stage clinical trial. Its rival SuperGen (Nasdaq: SUPG) said Dacogen didn't improve the survival rate of patients. SuperGen's stock closed down 14.63% to a low of $1.75.
Celgene Corporation is an integrated biopharmaceutical company.
SuperGen is a pharmaceutical company dedicated primarily to the discovery, development and commercialization of therapies to treat patients with cancer.
Sign up at EasyStockAlerts.com To Be Alerted To Your Breaking Stock News!
You May Also Be Interested In
- Scorpion Capital says short Twist Biosciences
- Samsung Plans As Much As $79 Billion In Shareholder Returns - Bloomberg
- Holcim said to acquire part of James Hardie's EU business
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
